---
title: "Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Safety questions"
description: "Safety questions on Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Monitoring, Safety management, and Side effects. Questions: Is a rise in lymphocytes on Imbruvica a sign of CLL progression? Do side effects resolve after an Imbruvica dose reduction (pooled analysis)? What are the most common side effects of Imbruvica in CLL/SLL? What are the most common grade 3 or higher side effects of Imbruvica? 8 further questions follow. 12 questions quoted from 11 sources."
canonical: "https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Safety questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)

Safety questions that apply to every indication of Imbruvica are on [Imbruvica (ibrutinib), all indications: Safety](https://www.evicenter.com/medical-information/imbruvica/safety).

## Monitoring

<a id="imbruvica-lymphocytosis"></a>

### Is a rise in lymphocytes on Imbruvica a sign of CLL progression?

> “Lymphocytosis is an increase in the number of lymphocytes in the blood. Therapies that interfere with trafficking and adhesion of malignant lymphocytes by disrupting B-cell signaling can result in treatment-related lymphocytosis.<sup>1,2</sup>
> Isolated asymptomatic lymphocytosis may be due to the mechanism of action of IMBRUVICA<sup>®</sup> and may not be a sign of disease progression.<sup>1,3</sup>
>
> Treatment-related lymphocytosis occurred in 66% of patients treated with single-agent IMBRUVICA<sup>®</sup> across the CLL/SLL registration studies<sup>4</sup>
>
> Lymphocytosis is defined as ≥50% increase from baseline and above absolute lymphocyte count of 5,000/mcL
> In the CLL/SLL registration studies, the onset of isolated lymphocytosis occurred during the first month of IMBRUVICA<sup>®</sup> therapy and resolved by a median of 14 weeks (range, 0.1 to 104 weeks)
> Lymphocytosis occurred in 7% of patients treated with IMBRUVICA<sup>®</sup> + BR vs 6% with placebo + BR
> Lymphocytosis occurred in 7% of patients treated with IMBRUVICA<sup>®</sup> + obinutuzumab vs 1% with chlorambucil + obinutuzumab”

Source: [IMBRUVICA: Treatment-Related Lymphocytosis - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/mechanism-of-action/treatment-related-lymphocytosis#:~:text=Lymphocytosis%20is%20an%20increase%20in,1%25%20with%20chlorambucil%20%2B%20obinutuzumab)

## Safety management

<a id="imbruvica-dose-reduction-ae-resolution"></a>

### Do side effects resolve after an Imbruvica dose reduction (pooled analysis)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “This analysis pooled data from the IMBRUVICA<sup>®</sup> arm of two multicenter studies of patients with treatment-naïve CLL/SLL. RESONATE™-2 included 136 patients who were 65 years or older and received single-agent IMBRUVICA<sup>®</sup>. iLLUMINATE™ included 113 patients who were 65 years or older or with coexisting medical conditions and received IMBRUVICA<sup>®</sup> in combination with obinutuzumab<sup>1</sup>”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=This%20analysis%20pooled%20data%20from,in%20combination%20with)

> “Patients with an AE leading
> to dose reduction per USPI*
> 21/248 (9%)”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=Patients%20with%20an%20AE%20leading,21%2F248%20%289%25%29)

> “No recurrence or recurred at lower grade: 16/21 (76%)
> Recurred at the same or higher grade: 5/21 (24%)”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=No%20recurrence%20or%20recurred%20at,or%20higher%20grade%3A%205%2F21%20%2824%25%29)

> “Of the 21 patients who required a dose reduction<sup>†‡§</sup>
>
> Initial AE resolution:
>
> for pooled IMBRUVICA<sup>®</sup>-treated patients
>
> 95%
> 20/21
>
> Initial AE that led to a dose modification was resolved in 95% of patients”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=Of%20the%2021%20patients%20who,resolved%20in%2095%25%20of%20patients)

> “Timing of AE outcomes, including resolution, recurrence, and discontinuation was not part of the evaluation. Dose modifications include a dose hold, followed by a dose reduction.
>
> Results from this analysis are descriptive in nature and have no implications regarding efficacy.
> These pooled analysis results are not included in the Prescribing Information for IMBRUVICA<sup>®</sup>.”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=Timing%20of%20AE%20outcomes%2C%20including,in%20the%20Prescribing%20Information%20for)

## Side effects

<a id="imbruvica-common-side-effects"></a>

### What are the most common side effects of Imbruvica in CLL/SLL?

> “The most common adverse reactions in patients with CLL/SLL receiving IMBRUVICA (≥ 30%) 
> were thrombocytopenia, diarrhea, fatigue, musculoskeletal pain, neutropenia, rash, anemia, 
> bruising, and nausea.”

Source: [IMBRUVICA: Prescribing information, page 11, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=11)

> “The most common adverse reactions (≥30%) in adult patients with B-cell malignancies were thrombocytopenia (55%)*, diarrhea (44%), fatigue (39%), musculoskeletal pain (39%), neutropenia (39%)*, rash (36%), anemia (35%)*, bruising (32%), and nausea (30%).”

Source: [IMBRUVICA: CLL and SLL Treatment, captured 2026-11-13](https://www.imbruvicahcp.com/cll#:~:text=The%20most%20common%20adverse%20reactions%20%28%E2%89%A530%25%29,bruising%20%2832%25%29%2C%20and%20nausea%20%2830%25%29.)

> “*Treatment-emergent decreases (all grades) were based on laboratory measurements.”

Source: [IMBRUVICA: CLL and SLL Treatment, captured 2026-11-13](https://www.imbruvicahcp.com/cll#:~:text=%2ATreatment%2Demergent%20decreases%20%28all%20grades%29%20were%20based%20on%20laboratory%20measurements.)

Note: The percentages are from pooled data in adults with B-cell malignancies; the Prescribing Information sentence lists the most common adverse reactions in CLL/SLL without percentages.

<a id="imbruvica-serious-side-effects"></a>

### What are the most common grade 3 or higher side effects of Imbruvica?

Applies to: Adults with B-cell malignancies, including CLL/SLL (pooled label safety data)

> “The most common grade ≥3 adverse reactions (≥5%) in adult patients with B-cell malignancies were neutropenia (21%)*, thrombocytopenia (14%)*, pneumonia (8%), and hypertension (8%).”

Source: [IMBRUVICA: CLL and SLL Treatment, captured 2026-11-13](https://www.imbruvicahcp.com/cll#:~:text=The%20most%20common%20grade%20%E2%89%A53,pneumonia%20%288%25%29%2C%20and%20hypertension%20%288%25%29.)

> “*Treatment-emergent decreases (all grades) were based on laboratory measurements.”

Source: [IMBRUVICA: CLL and SLL Treatment, captured 2026-11-13](https://www.imbruvicahcp.com/cll#:~:text=%2ATreatment%2Demergent%20decreases%20%28all%20grades%29%20were%20based%20on%20laboratory%20measurements.)

<a id="imbruvica-discontinuation-rates"></a>

### How often do CLL patients stop or reduce Imbruvica because of side effects?

> “Four to 10 percent of patients with CLL/SLL receiving IMBRUVICA discontinued treatment 
> due to adverse reactions. These included pneumonia, hemorrhage, atrial fibrillation, neutropenia, 
> arthralgia, rash, and thrombocytopenia. Adverse reactions leading to dose reduction occurred in 
> approximately 9% of patients.”

Source: [IMBRUVICA: Prescribing information, page 11, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=11)

<a id="imbruvica-long-term-side-effects"></a>

### What are the long-term side effects of Imbruvica over 10 years (RESONATE-2)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Most common treatment-emergent AEs across 10 years at the long-term analysis reported in RESONATE™-2 for the overall population”

Source: [IMBRUVICA: RESONATE-2 Long-Term 8-Year Safety, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/resonate-2/long-term-safety#:~:text=Most%20common%20treatment%2Demergent%20AEs%20across,RESONATE%E2%84%A2%2D2%20for%20the%20overall%20population)

> “10-year RESONATE™-2 long-term data are not included in the Prescribing Information for IMBRUVICA<sup>®</sup>. The timing for long-term follow-up was not prespecified, and the analysis was descriptive in nature.”

Source: [IMBRUVICA: RESONATE-2 Long-Term 8-Year Safety, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/resonate-2/long-term-safety#:~:text=10%2Dyear%20RESONATE%E2%84%A2%2D2%20long%2Dterm%20data%20are,analysis%20was%20descriptive%20in%20nature.)

> “AEs (all grades) occurring in ≥15% of patients receiving IMBRUVICA<sup>®</sup> (n=135)<sup>1</sup>
>
> Adverse Event	All Grades (%)
> Diarrhea	52
> Fatigue	41
> Cough	39
> Nausea	32
> Arthralgia	31
> Peripheral edema	31
> Hypertension	30
> Pyrexia	30
> Upper respiratory tract infection	30
> Pneumonia	29
> Anaemia	27
> Urinary tract infection	26
> Weight decreased	25
> Atrial fibrillation	24
> Constipation	23
> Vomiting	22
> Back pain	21
>
> Adverse Event	All Grades (%)
> Fall	21
> Muscle spasms	21
> Dry eye	20
> Contusion	19
> Dizziness	19
> Neutropenia	19
> Cataract	18
> Decreased appetite	18
> Abdominal pain	17
> Basal cell carcinoma	17
> Hyperuricaemia	17
> Pain in extremity	17
> Vision blurred	17
> Conjunctivitis	16
> Dyspnoea	16
> Increased tendency to bruise	16
> Dyspepsia	16
> Epistaxis	16”

Source: [IMBRUVICA: RESONATE-2 Long-Term 8-Year Safety, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/resonate-2/long-term-safety#:~:text=AEs%20%28all%20grades%29%20occurring%20in,16)

> “ARs (grades ≥3) occurring in ≥5% of patients receiving IMBRUVICA<sup>®</sup> (n=135)<sup>1</sup>
>
> Adverse Event	Grades ≥3 (%)
> Pneumonia	20
> Neutropenia	13
> Hypertension	12
> Anemia	7
> Cataract	7
>
> Adverse Event	Grades ≥3 (%)
> Hyponatremia	7
> Atrial fibrillation	6
> Syncope	6
> Diarrhea	5
> Cardiac failure	5
>
> AE rates for the chlorambucil group were not captured in the 10-year analysis. Please refer to the primary analysis of RESONATE™-2 for these data.”

Source: [IMBRUVICA: RESONATE-2 Long-Term 8-Year Safety, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/resonate-2/long-term-safety#:~:text=ARs%20%28grades%20%E2%89%A53%29%20occurring%20in,of%20RESONATE%E2%84%A2%2D2%20for%20these%20data.)

Note: Each percentage is the share of the 135 patients treated with Imbruvica who had the event at any time over up to 10 years of follow-up.

<a id="imbruvica-pooled-5-year-safety"></a>

### Do Imbruvica side effects change over 5 years of treatment (pooled CLL data)?

> “In pooled data from multiple open-label rollover and follow-up studies in both treatment-naïve and relapsed/refractory CLL/SLL patients (N=808), the median treatment duration was 51 months (range 0.2 to 98 months). Due to types of events collected and less frequent clinic visits, limited data were collected from 1 follow-up study.”

Source: [IMBRUVICA: Pooled Long-Term Safety, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/pooled-long-term-safety#:~:text=In%20pooled%20data%20from%20multiple,collected%20from%201%20follow%2Dup%20study.)

> “Data suggest AR rates generally decreased or remained stable over time, except for hypertension
> Patients had the option to enroll in open-label rollover and follow-up studies, which were not conducted with the same methodology as the parent studies. The cumulative rate of hypertension increased over time with IMBRUVICA<sup>®</sup> treatment”

Source: [IMBRUVICA: Pooled Long-Term Safety, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/pooled-long-term-safety#:~:text=Data%20suggest%20AR%20rates%20generally,treatment)

> “The safety data from long-term treatment with IMBRUVICA<sup>®</sup> over 5 years of 1,284 patients were analyzed. The median treatment duration was 51 months (range, 0.2 to 98 months) for CLL/SLL. The cumulative rate of hypertension increased over time. The prevalence for Grade 3 or greater hypertension was 4% (year 0-1), 7% (year 1-2), 9% (year 2-3), 9% (year 3-4), and 9% (year 4-5); the overall incidence for the 5-year period was 11%.”

Source: [IMBRUVICA: Pooled Long-Term Safety, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/pooled-long-term-safety#:~:text=The%20safety%20data%20from%20long%2Dterm,the%205%2Dyear%20period%20was%2011%25.)

> “*Additional safety analysis conducted pursuant to FDA postmarketing requirements.”

Source: [IMBRUVICA: Pooled Long-Term Safety, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/pooled-long-term-safety#:~:text=%2AAdditional%20safety%20analysis%20conducted%20pursuant%20to%20FDA%20postmarketing%20requirements.)

Note: The 1,284-patient long-term analysis, the source of the Grade 3 or greater hypertension rates, included patients with B-cell malignancies (warnings and precautions page); the rollover and follow-up pool of CLL/SLL patients is N=808.

<a id="imbruvica-resonate2-side-effects"></a>

### What side effects occurred with Imbruvica vs chlorambucil (RESONATE-2)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Median duration of exposure was 17.4 months for IMBRUVICA<sup>®</sup> vs 7.1 months for chlorambucil<sup>1</sup>
>
>  	IMBRUVICA<sup>®</sup> (n=135)	Chlorambucil (n=132)
> Adverse Reaction	All Grades (%)	Grade 3 or Higher (%)	All Grades (%)	Grade 3 or Higher (%)
> Gastrointestinal disorders	 
> Diarrhea	42	4	17	0
> Nausea	22	1	39	1
> Constipation	16	1	16	0
> Stomatitis*	14	1	4	1
> Vomiting	13	0	20	1
> Abdominal pain	13	3	11	1
> Dyspepsia	11	0	2	0
> Musculoskeletal and connective tissue disorders	 
> Musculoskeletal pain*	36	4	20	0
> Arthralgia	16	1	7	1
> Muscle spasms	11	0	5	0
> General disorders and administration site conditions	 
> Fatigue	30	1	38	5
> Peripheral edema	19	1	9	0
> Pyrexia	17	0	14	2
> Respiratory, thoracic, and mediastinal disorders	 
> Cough	22	0	15	0
> Dyspnea	10	1	10	0
> Skin and subcutaneous tissue disorders	 
> Rash*	21	4	12	2
> Bruising*	19	0	7	0
> Eye disorders	 
> Dry eye	17	0	5	0
> Lacrimation increased	13	0	6	0
> Vision blurred	13	0	8	0
> Visual acuity reduced	11	0	2	0
> Infections and infestations	 
> Upper respiratory tract infection	17	2	17	2
> Skin infection*	15	2	3	1
> Pneumonia*	14	8	7	4
> Urinary tract infections	10	1	8	1
> Vascular disorders	 
> Hypertension*	14	4	1	0
> Nervous system disorders	 
> Headache	12	1	10	2
> Dizziness	11	0	12	1
> Investigations	 
> Weight decreased	10	0	12	0
>
> Subjects with multiple events for a given ADR term are counted once only for each ADR term.
>
> The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA<sup>®</sup> arm.
>
> Includes multiple ADR terms.”

Source: [IMBRUVICA: RESONATE-2 Adverse Reactions, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/resonate-2#:~:text=Median%20duration%20of%20exposure%20was,Includes%20multiple%20ADR%20terms.)

> “Treatment-emergent decrease in hematologic measures<sup>1</sup>
> RESONATE™-2 Trial
>
> Median duration of exposure was 17.4 months for IMBRUVICA<sup>®</sup> vs 7.1 months for chlorambucil<sup>1</sup>
>
>  	IMBRUVICA<sup>®</sup> (n=135)	Chlorambucil (n=132)
> Adverse Reaction	All Grades (%)	Grade 3 or Higher (%)	All Grades (%)	Grade 3 or Higher (%)
> Neutrophils Decreased	55	28	67	31
> Platelets Decreased	47	7	58	14
> Hemoglobin Decreased	36	0	39	2
>
> Treatment-emergent Grade 4 thrombocytopenia (1% in the IMBRUVICA<sup>®</sup> arm vs 3% in the chlorambucil arm) and neutropenia (11% in the IMBRUVICA<sup>®</sup> arm vs 12% in the chlorambucil arm) occurred in patients.”

Source: [IMBRUVICA: RESONATE-2 Adverse Reactions, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/resonate-2#:~:text=Treatment%2Demergent%20decrease%20in%20hematologic,chlorambucil%20arm%29%20occurred%20in%20patients.)

Note: Table columns are Imbruvica all grades, Imbruvica Grade 3 or higher, chlorambucil all grades, and chlorambucil Grade 3 or higher (% of patients).

<a id="imbruvica-resonate-side-effects"></a>

### What side effects occurred with Imbruvica vs ofatumumab in relapsed CLL (RESONATE)?

Applies to: Adults with previously treated (relapsed or refractory) CLL/SLL

> “Median duration of exposure was 8.6 months for IMBRUVICA<sup>®</sup> vs 5.3 months for ofatumumab<sup>1</sup>
>
>  	IMBRUVICA<sup>®</sup> (n=195)	Ofatumumab (n=191)
> Adverse Reactions	All Grades (%)	Grade 3 or Higher (%)	All Grades (%)	Grade 3 or Higher (%)
> Gastrointestinal disorders	 
> Diarrhea	48	4	18	2
> Nausea	26	2	18	0
> Stomatitis*	17	1	6	1
> Constipation	15	0	9	0
> Vomiting	14	0	6	1
> Musculoskeletal and connective tissue disorders	 
> Musculoskeletal pain*	28	2	18	1
> Arthralgia	17	1	7	0
> Muscle spasms	13	0	8	0
> Skin and subcutaneous tissue disorders	 
> Rash*	24	3	13	0
> Petechiae	14	0	1	0
> Bruising*	12	0	1	0
> General disorders and administration site conditions	 
> Pyrexia	24	2	15	2<sup>†</sup>
> Respiratory, thoracic and mediastinal disorders	 
> Cough	19	0	23	1
> Dyspnea	12	2	10	1
> Infections and infestations	 
> Upper respiratory tract infection	16	1	11	2<sup>†</sup>
> Pneumonia*	15	12<sup>†</sup>	13	10<sup>†</sup>
> Sinusitis*	11	1	6	0
> Urinary tract infection	10	4	5	1
> Nervous system disorders	 
> Headache	14	1	6	0
> Dizziness	11	0	5	0
> Injury, poisoning and procedural complications	 
> Contusion	11	0	3	0
> Eye disorders	 
> Vision blurred	10	0	3	0
>
> The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA<sup>®</sup> arm.
>
> Includes multiple ADR terms.
>
> †
> Includes 3 events of pneumonia with fatal outcome in each arm, and 1 event of pyrexia and upper respiratory tract infection with a fatal outcome in the ofatumumab arm.”

Source: [IMBRUVICA: RESONATE - Adverse Reactions, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/resonate#:~:text=Median%20duration%20of%20exposure%20was,outcome%20in%20the%20ofatumumab%20arm.)

> “Treatment-emergent decrease in hematologic measures<sup>1</sup>
> RESONATE™ Trial
>
> Median duration of exposure was 8.6 months for IMBRUVICA<sup>®</sup> vs 5.3 months for ofatumumab<sup>1</sup>
>
>  	IMBRUVICA<sup>®</sup> (n=195)	ofatumumab (n=191)
> Adverse Reaction	All Grades (%)	Grade 3 or 4 (%)	All Grades (%)	Grade 3 or 4 (%)
> Neutrophils decreased	51	23	57	26
> Platelets decreased	52	5	45	10
> Hemoglobin decreased	36	0	21	0
>
> Treatment-emergent Grade 4 thrombocytopenia (2% in the IMBRUVICA<sup>®</sup> arm vs 3% in the ofatumumab arm) and neutropenia (8% in the IMBRUVICA<sup>®</sup> arm vs 8% in the ofatumumab arm) occurred in patients.<sup>1</sup>”

Source: [IMBRUVICA: RESONATE - Adverse Reactions, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/resonate#:~:text=Treatment%2Demergent%20decrease%20in%20hematologic,the%20ofatumumab%20arm%29%20occurred%20in)

Note: Table columns are Imbruvica all grades, Imbruvica Grade 3 or higher (Grade 3 or 4 in the hematologic table), ofatumumab all grades, and ofatumumab Grade 3 or higher (% of patients).

<a id="imbruvica-e1912-side-effects"></a>

### What side effects occurred with Imbruvica plus rituximab vs FCR (E1912)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Median exposure to IMBRUVICA<sup>®</sup> + rituximab was 34.3 months vs 4.7 months for FCR<sup>1</sup>
>
>  	IR (n=352)	FCR (n=158)
> Adverse Drug Reaction Term	All Grades (%)	Grade 3 or Higher* (%)	All Grades (%)	Grade 3 or Higher* (%)
> General disorders and administration site conditions	 
> Fatigue	80	2	78	3
> Peripheral edema	28	1	17	0
> Pyrexia	27	1	27	1
> Pain	23	2	8	0
> Musculoskeletal and connective tissue disorders	 
> Musculoskeletal pain<sup>†</sup>	61	5	35	2
> Arthralgia	41	5	10	1
> Gastrointestinal disorders	 
> Diarrhea	53	4	27	1
> Nausea	40	1	64	1
> Stomatitis<sup>†</sup>	22	1	8	1
> Abdominal pain<sup>†</sup>	19	2	10	1
> Vomiting	18	2	28	0
> Constipation	17	0	32	0”

Source: [IMBRUVICA: E1912 - Adverse Reactions, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/e1912#:~:text=Median%20exposure%20to,0)

> “Skin and subcutaneous tissue disorders	 
> Rash<sup>†</sup>	49	4	29	5
> Bruising<sup>†</sup>	36	1	4	1
> Vascular disorders	 
> Hypertension<sup>†</sup>	42	19	22	6
> Hemorrhage<sup>†</sup>	31	2	8	1
> Nervous system disorders	 
> Headache	40	1	27	1
> Dizziness	21	1	13	1
> Peripheral neuropathy<sup>†</sup>	19	1	13	1”

Source: [IMBRUVICA: E1912 - Adverse Reactions, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/e1912#:~:text=Skin%20and%20subcutaneous%20tissue%20disorders,1)

> “Respiratory, thoracic, and mediastinal disorders	 
> Cough	32	0	25	0
> Dyspnea	22	2	21	1
> Infections and infestations	 
> Upper respiratory tract infection	29	1	19	2
> Skin infection<sup>†</sup>	16	1	3	1
> Metabolism and nutrition disorders	 
> Hyperuricemia	19	1	4	0
> Decreased appetite	15	0	20	1
> Psychiatric disorders	 
> Insomnia	16	1	19	1”

Source: [IMBRUVICA: E1912 - Adverse Reactions, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/e1912#:~:text=Respiratory%2C%20thoracic%2C%20and%20mediastinal%20disorders,1)

> “Includes multiple adverse drug reaction terms.”

Source: [IMBRUVICA: E1912 - Adverse Reactions, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/e1912#:~:text=Includes%20multiple%20adverse%20drug%20reaction%20terms.)

> “Table 14:  Select Laboratory Abnormalities (≥ 15% Any Grade), New or Worsening from 
> Baseline in Patients Receiving IMBRUVICA (E1912) 
>
> IMBRUVICA + Rituximab 
>
> (N=352) 
> Fludarabine + 
> Cyclophosphamide + 
> Rituximab 
> (N=158) 
> All Grades 
> (%) 
> Grade 3 or 4 
> (%) 
> All Grades 
> (%) 
> Grade 3 or 4 
> (%) 
> Hematology abnormalities 
>      Neutrophils decreased 
>      Platelets decreased 
>      Hemoglobin decreased 
>
> 53 
> 43 
> 26 
>
> 30 
> 7 
> 0 
>
> 70 
> 69 
> 51 
>
> 44 
> 25 
> 2 
> Chemistry abnormalities 
>      Creatinine increased 
>      Bilirubin increased 
>      AST increased 
>
> 38 
> 30 
> 25 
>
> 1 
> 2 
> 3 
>
> 17 
> 15 
> 23 
>
> 1 
> 0 
> <1 
> Based on laboratory measurements per IWCLL criteria.”

Source: [IMBRUVICA: Prescribing information, page 21, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=21)

Note: Table columns on the E1912 page are Imbruvica plus rituximab (IR) all grades, IR Grade 3 or higher, FCR all grades, and FCR Grade 3 or higher (% of patients). FCR is fludarabine, cyclophosphamide, and rituximab. The laboratory values are from Table 14 of the Prescribing Information, whose PDF text lists the row names of each section and then each column of values in the same order (Imbruvica plus rituximab all grades, Grade 3 or 4, then FCR all grades, Grade 3 or 4). The hematology rows of the E1912 page are not quoted because the page labels its second row Peripheral edema, where Table 14 lists platelets decreased with the same values.

<a id="imbruvica-illuminate-side-effects"></a>

### What side effects occurred with Imbruvica plus obinutuzumab (iLLUMINATE)?

Applies to: Adults with previously untreated (first-line) CLL/SLL

> “Median duration of exposure was 29.3 months for IMBRUVICA<sup>®</sup> + obinutuzumab vs 5.1 months for chlorambucil + obinutuzumab<sup>1</sup>
>
>  	IMBRUVICA<sup>®</sup> + obinutuzumab (n=113)	chlorambucil + obinutuzumab (n=115)
> Adverse Reactions	All Grades (%)	Grade 3 or Higher (%)	All Grades (%)	Grade 3 or Higher (%)
> Blood and lymphatic system disorders	 
> Neutropenia*	48	39	64	48
> Thrombocytopenia*	36	19	28	11
> Anemia	17	4	25	8
> Skin and subcutaneous tissue disorders	 
> Rash*	36	3	11	0
> Bruising*	32	3	3	0
> Gastrointestinal disorders	 
> Diarrhea	34	3	10	0
> Constipation	16	0	12	1
> Nausea	12	0	30	0
> Musculoskeletal and connective tissue disorders	 
> Musculoskeletal pain*	33	1	23	3
> Arthralgia	22	1	10	0
> Muscle spasms	13	0	6	0
> Respiratory, thoracic, and mediastinal disorders	 
> Cough	27	1	12	0
> Injury, poisoning and procedural complications	 
> Infusion related reaction	25	2	58	8
> Vascular disorders	 
> Hemorrhage*	25	1	9	0
> Hypertension*	17	4	4	3
> Infections and infestations	 
> Pneumonia*	16	9	9	4<sup>†</sup>
> Upper respiratory tract infection	14	1	6	0
> Skin infection*	13	1	3	0
> Urinary tract infection	12	3	7	1
> Nasopharyngitis	12	0	3	0
> Conjunctivitis	11	0	2	0
> Metabolism and nutrition disorders	 
> Hyperuricemia	13	1	0	0
> Cardiac disorders	 
> Atrial fibrillation	12	5	0	0
> General disorders and administration site conditions	 
> Pyrexia	19	2	26	1
> Fatigue	18	0	17	2
> Peripheral edema	12	0	7	0
> Psychiatric disorders	 
> Insomnia	12	0	4	0
>
> The data are not an adequate basis for comparison of ADR rates between treatment arms.
>
> The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA<sup>®</sup> arm.
>
> Includes multiple ADR terms.
>
> †
> Includes one event with a fatal outcome.”

Source: [IMBRUVICA: iLLUMINATE - Adverse Reactions, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/illuminate#:~:text=Median%20duration%20of%20exposure%20was,event%20with%20a%20fatal%20outcome.)

Note: Table columns are Imbruvica plus obinutuzumab all grades, Imbruvica plus obinutuzumab Grade 3 or higher, chlorambucil plus obinutuzumab all grades, and chlorambucil plus obinutuzumab Grade 3 or higher (% of patients).

<a id="imbruvica-helios-side-effects"></a>

### What side effects occurred with Imbruvica plus bendamustine-rituximab (HELIOS)?

Applies to: Adults with previously treated (relapsed or refractory) CLL/SLL

> “Median duration of exposure was 14.7 months for IMBRUVICA<sup>®</sup> + BR vs 12.8 months for placebo + BR<sup>1</sup>
>
>  	IMBRUVICA<sup>®</sup> + BR (n=287)	Placebo + BR (n=287)
> Adverse Reactions	All Grades (%)	Grade 3 or Higher (%)	All Grades (%)	Grade 3 or Higher (%)
> Blood and lymphatic system disorders	 
> Neutropenia*	66	61	60	56<sup>†</sup>
> Thrombocytopenia*	34	16	26	16
> Skin and subcutaneous tissue disorders	 
> Rash*	32	4	25	1
> Bruising*	20	<1	8	<1
> Gastrointestinal disorders	 
> Diarrhea	36	2	23	1
> Abdominal pain	12	1	8	<1
> Musculoskeletal and connective tissue disorders	 
> Musculoskeletal pain*	29	2	20	0
> Muscle spasms	12	<1	5	0
> General disorders and administration site conditions	 
> Pyrexia	25	4	22	2
> Vascular disorders	 
> Hemorrhage*	19	2<sup>†</sup>	9	1
> Hypertension*	11	5	5	2
> Infections and infestations	 
> Bronchitis	13	2	10	3
> Skin infection*	10	3	6	2
> Metabolism and nutrition disorders	 
> Hyperuricemia	10	2	6	0
>
> The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA<sup>®</sup> arm.
>
> Includes multiple ADR terms.
>
> <1 used for frequency above 0 and below 0.5%.
>
> †
> Includes 2 events of hemorrhage with fatal outcome in the IMBRUVICA<sup>®</sup> arm and 1 event of neutropenia with a fatal outcome in the placebo + BR arm.”

Source: [IMBRUVICA: HELIOS - Adverse Reactions, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/helios#:~:text=Median%20duration%20of%20exposure%20was,the%20placebo%20%2B%20BR%20arm.)

Note: Table columns are Imbruvica plus BR all grades, Imbruvica plus BR Grade 3 or higher, placebo plus BR all grades, and placebo plus BR Grade 3 or higher (% of patients). BR is bendamustine and rituximab.

## Related pages
- [Medical information: Imbruvica (ibrutinib): Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)
- [Indication](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/guidelines)
